clinical trial · NCT07577843
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC·phase3·recruiting·n = 460
Crohn DiseaseJNJ-78934804Guselkumab
brief summary
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).
started
May 22, 2026
primary completion
Jun 12, 2028
completion
Jul 12, 2030
last updated
Jul 6, 2026
official title
A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol